PBA
CRNX icon

Paradigm Biocapital Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,210,774
Closed -$103M – 38
2025
Q4 		$103M Sell
2,210,774
-340,000
-13% -$15.1M 2.63% 14
2025
Q3 		$106M Buy
2,550,774
+207,221
+9% +$6.63M 3.02% 10
2025
Q2 		$67.4M Buy
2,343,553
+397,385
+20% +$12.3M 2.88% 11
2025
Q1 		$65.3M Buy
1,946,168
+35,407
+2% +$1.32M 2.99% 9
2024
Q4 		$97.7M Sell
1,910,761
-605,925
-24% -$33.9M 3.4% 10
2024
Q3 		$129M Buy
2,516,686
+3,384
+0.1% +$175K 4.35% 5
2024
Q2 		$113M Sell
2,513,302
-611,447
-20% -$28.2M 4.31% 8
2024
Q1 		$146M Buy
3,124,749
+811,830
+35% +$31.8M 5.15% 5
2023
Q4 		$82.3M Buy
2,312,919
+134,182
+6% +$4.11M 3.85% 12
2023
Q3 		$64.8M Buy
2,178,737
+783,735
+56% +$16.2M 4.4% 10
2023
Q2 		$25.1M Buy
1,395,002
+261,220
+23% +$5.21M 1.94% 19
2023
Q1 		$18.2M Buy
1,133,782
+243,677
+27% +$4.51M 1.73% 21
2022
Q4 		$16.3M Buy
890,105
+370,849
+71% +$6.53M 1.91% 20
2022
Q3 		$10.2M Buy
+519,256
New +$10.6M 1.36% 23

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Paradigm Biocapital Advisors's CRNX Position: Q1 2026 in Review

Paradigm Biocapital Advisors sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 2,210,774 shares — an estimated $103M sold.

Paradigm Biocapital Advisors first reported a position in CRNX in Q3 2022 and held it in 14 quarters. The position peaked at $146M in Q1 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Paradigm Biocapital Advisors reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 2,210,774 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $103M.
  • Paradigm Biocapital Advisors first reported a position in Crinetics Pharmaceuticals in Q3 2022 and held it in 14 quarters.
  • Paradigm Biocapital Advisors's Crinetics Pharmaceuticals position peaked at $146M in Q1 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.